Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-08-07
2007-08-07
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387500, C530S388100, C530S388800, C530S391700, C435S069600, C435S328000, C435S330000, C424S133100, C424S137100, C424S141100, C424S155100, C424S181100
Reexamination Certificate
active
10089500
ABSTRACT:
The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and diagnosis of the antibody and the derivatives.
REFERENCES:
patent: 5006470 (1991-04-01), Yamaguchi et al.
patent: 5091178 (1992-02-01), Hellstrom et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5610280 (1997-03-01), Brandt et al.
patent: 5730981 (1998-03-01), Bosslet et al.
patent: 5750078 (1998-05-01), Shitara et al.
patent: 6437098 (2002-08-01), Shitara et al.
patent: 0 280 209 (1988-08-01), None
patent: 0 493 686 (1992-07-01), None
patent: 0 533 199 (1993-03-01), None
patent: 533199 (1993-03-01), None
patent: 0 867 190 (1998-09-01), None
patent: 5-304989 (1993-11-01), None
patent: WO 91/09967 (1991-07-01), None
Co et al. Nature, 351:501-502, 1991.
Fundamental Immunology, William E. Paul, M.D. ed., 3rd ed., pp. 242, 292-295, 1993.
Chapman et al. Cancer Research, 50:1503-1509, Mar. 1, 1990.
LeBerthon et al. Cancer Research, 51:2694-2698, 1991.
Hanai et al. Cancer Chemotherapy and Pharmacology, 46 (Suppl):S13-S17, Jun. 2000.
Nakamura et al. Cancer, 80(12 Suppl):2650-2655, Dec. 15, 1997.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Alberts et al. Molecular Biology of the Cell, 3rd Ed. pp. 1216-1217, 1994.
Immunology, 3rdEdition, “Engineered Monoclonal Antibodies”, Janis Kuby, 1997, W.H. Freeman and Company, New York.
Webber et al, “Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-tax antibody: comparison with its single-chain analog”, Molecular Immunology, vol. 32 1995, pp. 249-258.
Moutel, “Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2)”, HYBRIDOMA, vol. 16, 1997, pp. 335-346.
Morrison et al, “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains”, Proc. Natl. Acad. Sci. U.S.A., vol. 81, 1984, pp. 6851-6855.
Jones et al, “Replacing the complementarity-determining regions in a human antibody with those from a mouse”, NATURE, vol. 321, 1986, pp. 522-525.
Presentini et al, Journal of Immunoassay, 1995, vol. 16, No. 3, pp. 309-324.
Supplementary Partial European Search Report dated May 10, 2005 issued in connection with EP 00 96 2981.7.
Scott et al, Current Opinion in Immunology, 1997. vol. 9, No. 5, pp. 717-722.
Shitara et al, Cancer Immunology Immunotherapy, 1993, vol. 36, No. 6, pp. 373-380.
Ojima et al, Tohoku J. Exp. Med., 1998, vol. 185, No. 2, pp. 89-100.
Shitara et al, Cancer Immunol Immunother, 1993, vol. 36, No. 6, pp. 373-380.
Scott et al, Current Opinion in Immunology, 1997, vol. 9, No. 5, pp. 717-722.
Alpaugh et al, Medical Oncology, 1998, vol. 15, No. 3, pp. 191-198.
Nasi et al, Melanoma Research, 1997, vol. 7, No. suppl 2, pp. S155-S162.
Chapman et al, Cancer Immunol Immunother, 1994, vol. 39, No. 3, pp. 198-204.
Dippold et al, European Journal of Cancer, 1992, vol. 28A, No. 10, pp. 1605-1610.
A Process for the Production of Humanized Chimaeric Antibody, Current Opinion in Therapeutic Patents, 993, vol. 3, No. 9, pp. 1357-1358.
Supplementary European Search Report dated Aug. 18, 2005 issued in corresponding EP 00 96 2981.7.
Hanai Nobuo
Nakamura Kazuyasu
Niwa Rinpel
Shitara Kenya
Blanchard David J.
Helms Larry R.
Kyowa Hakko Kogyo Co. Ltd.
Nixon & Vanderhye P.C.
LandOfFree
Complementarity determining region-grafted antibody against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complementarity determining region-grafted antibody against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complementarity determining region-grafted antibody against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3889105